Your Pharmacy Contract Is About to Become Visible: What the New Federal Transparency Rule Changes
For many employers, pharmacy costs have been a hard part of the health plan to see clearly. That is changing. A federal rule finalized by the U.S. Department of Labor on October 29, 2026, and published in the Federal Register on November 2, requires detailed disclosure of the money behind certain pharmacy services contracts. The contracts themselves come into view too, because the rule gives plans an audit right that reaches them.
The rule takes effect January 4, 2027, and applies to plan years beginning on or after July 1, 2027. In practical terms, much of the money stops being invisible in 2027: eligible employers will gain a clearer view of fees, rebates, spreads, and other payments behind the contract.
For CFOs, HR leaders, and benefits consultants, this is a chance to turn disclosure into better decisions. Prescription drug cost trend is projected at about 11.5% for 2027, according to Segal’s cost trend survey. Meanwhile, the 2026 KFF Employer Health Benefits Survey reports average annual family premiums of $28,303, up 5% from 2025. Better information does not guarantee savings, but it gives plan fiduciaries a stronger basis to ask questions, compare compensation, and act.

Know whether the rule applies to your plan
The final rule covers self-insured group health plans of “specified large employers.” In practice that means an average of at least 100 employees in the preceding calendar year, with at least one employee on January 1, counting employees across related employers under the tax code’s common-ownership aggregation rules. It also covers “specified large plans,” which average at least 100 participants, rounded down. Fully insured plans are excluded, as are plans sponsored by drug manufacturers, distributors, wholesalers, and related entities, and some categories were reserved for future rulemaking. Small self-insured plans are not covered by this rule, though they still receive the more general statutory disclosures.
A level-funded arrangement may look like a self-funded plan in some respects, but employers should not assume the rule applies, or does not apply, based on the plan’s label alone. Confirm the arrangement’s legal and funding status with counsel. Level-funded health plans may be an on-ramp for smaller employers exploring self-funding, but they are not a substitute for understanding the terms, risk, and disclosure duties of a specific contract. For employers weighing the level funded plan pros and cons, contract transparency belongs on the checklist.
If you are a smaller employer reading this and thinking the rule does not reach you, you are right about the disclosure requirement and wrong about the economics. The money in your pharmacy contract does not become less real because the obligation stops at 100 employees. What changes is your leverage: you can ask, in your own negotiation, for the same detail larger plans will now be entitled to see.
The disclosure obligation falls on the entity that contracts with the plan to provide pharmacy services and reasonably expects at least $1,000 in direct or indirect compensation. If a third-party administrator, carrier, or other entity contracts to provide those services, that contracting entity must obtain the required information from the vendor that performs the work.
That distinction matters in a TPA health plan: ask which party holds the pharmacy services contract and who is responsible for gathering and delivering the disclosures. Do not assume the entity handling day-to-day administration is automatically the covered provider.
Where does that leave a third-party administrator (TPA)? It depends entirely on how the administrator is structured, and that difference is about to become visible. Many TPAs hold the pharmacy services contract themselves, often bundling the drug benefit into their own arrangement. Under this rule, a TPA that contracts with the plan to provide pharmacy services is the covered service provider. That means the disclosures, the semiannual reporting cycle, the audit right, and the fiduciary monitoring duty all land on that administrator. For a TPA that owns the pharmacy relationship, that is a real operational and compliance exposure, not a paperwork exercise.
Quilt Benefits is structured differently. Quilt is a third-party administrator and does not hold the pharmacy services contract; that contract sits with a separate third-party entity. The disclosure duty runs to that entity, and the reports reach the plan through the party holding the relationship. Because the drug contract is not bundled into the administration agreement, the new obligations do not sit with Quilt.
So the question worth asking any administrator before renewal is direct: do you hold the pharmacy services contract yourself, or does a separate entity? The answer tells you who carries the new obligations, and it tells you something about how the arrangement is built. Because the rule determines coverage by function rather than by what an entity calls itself, confirm the answer in your own arrangement rather than assuming either way.
See the compensation behind the contract
The rule requires more than a broad summary of pharmacy costs. Initial disclosures must describe services, including copay accumulator or maximizer programs, and compensation by type, including direct compensation in total and by service.
The disclosures also include manufacturer payments such as rebates, fees, and alternative discounts, both in aggregate and for each drug. They must show how much is passed through to the plan and how much is retained. For each drug on the formulary, identified by National Drug Code, spread compensation must show what the plan pays, what the pharmacy receives, and the difference. Reports must also show spread in aggregate and by retail, mail order, and specialty channels. Ask for the codes to line up with what your claims system already uses, since the rule does not spell out a code format.
Other required disclosures cover copay clawbacks and other retroactive pharmacy adjustments; compensation expected upon termination; formulary placement incentives and each drug’s net price per fill or course of treatment; whether the vendor expects to act as a fiduciary; and the plan’s audit rights.
The information must be provided in plain language, and the Department of Labor treats undefined jargon as insufficient. Machine-readable delivery is available when the plan fiduciary asks for it, within a reasonable time, rather than automatically with every disclosure, so ask. If compensation in any category exceeds its estimate by 5% or more, or a lower figure the parties agree to in writing, the vendor must identify the overage and explain why. Amounts already passed through to the plan do not count toward that threshold.

Use the disclosure schedule to your advantage
Before entering into, renewing, or extending a covered contract, plans must receive initial disclosures. For renewals and extensions, providing them 90 days in advance is considered reasonable, and the parties can agree to a longer window. For brand-new contracts there is no fixed number of days: the standard is reasonably in advance. Either way, renewal planning matters, because a disclosure delivered at the last minute leaves little time for meaningful review.
After the contract starts, reports are due at least semiannually, within 30 days after the end of each reporting period. A plan may request quarterly reporting. Fiduciaries should treat these reports as a recurring review, not a file to store and forget.
The rule also provides an annual audit right. The plan can choose and pay an auditor, while the vendor must confirm the request within 10 business days and, absent extraordinary circumstances, produce claims and transaction-level data along with its contracts with pharmacies, manufacturers, and rebate aggregators within 60 calendar days. The vendor bears the cost of producing those materials. The audit is limited to verifying the accuracy of the disclosures for the periods they cover, so it is not an open-ended fishing expedition.
Contracts must also provide advance notice of formulary changes expected to increase manufacturer payments by 5% or more, along with notice that the plan may terminate on reasonably short notice. The Department of Labor deliberately declined to set a fixed number of days for that advance notice, so the contract should specify one. A contract is not considered reasonable unless the plan can terminate without penalty on reasonably short notice.
Protect fiduciary oversight with a clear process
Plan fiduciaries must obtain and review initial disclosures before contracting and determine that both the contract and compensation are reasonable. Their responsibility continues: they must monitor ongoing reports and exercise the audit rights available to the plan.
If a vendor fails to comply, limited fiduciary protection is available, and it depends on taking documented steps. The fiduciary must ask for a written correction, and if the problem is not fixed within 90 days, notify the Department of Labor within 30 days after the earlier of the vendor’s refusal or that 90-day mark. The fiduciary must also document its decision whether to terminate or continue the contract, including the alternatives it weighed. Two limits are worth stating plainly: this protection covers the plan fiduciary, not the vendor, and the Department of Labor declined to extend it to third-party administrators.
This is where a practical review process matters. Assign responsibility for receiving disclosures, checking data against contract estimates, escalating unexplained differences, and recording decisions. CFOs need a defensible view of plan costs; HR needs a workable process that does not create needless administrative churn. Employees benefit when employers can evaluate costs without making coverage decisions in the dark.
Prepare now, not at the next renewal
Use the time before applicability to get your contract and governance process ready:

Build the 90-day window into renewals. Work backward from contract dates so disclosures arrive early enough for review.
Negotiate usable audit rights and penalty-free termination. Confirm the contract supports annual audits and termination on reasonably short notice without a penalty.
Set lower thresholds where practical. The rule uses two different 5% tests with different bases: one for explaining why a category of compensation exceeded its estimate, and a separate one for advance notice of certain formulary changes. Do not conflate them. Employers can negotiate lower thresholds in writing to flag material changes sooner.
Create a documented report review. Assign owners, compare reported compensation with estimates, track questions and responses, and record decisions.
Coordinate with your broker and counsel. Your broker advises on strategy; your plan’s administrative partners help run the plan. Review your own contracts with counsel and confirm who must obtain and deliver each disclosure.
This article is information, not legal advice, and it is not a substitute for reading the rule or your own contracts. What the rule requires of a specific plan depends on that plan’s funding structure, size, and contract terms. Employers should have counsel review their own arrangements and confirm the right compliance steps before relying on any summary, including this one.
Make pharmacy transparency one cost lever, not the whole strategy
A transparent pharmacy contract is a powerful starting point, not a complete cost strategy. Quilt Benefits is a third-party administrator (TPA) built around 100% access to plan data and one integrated process across five cost levers: pharmacy transparency, high-cost specialty drugs, GLP-1s, large claim management, and stop loss management.
Quilt Benefits reports potential savings of up to 30% across its approach and 48% savings on large claimants; results vary by employer. The goal is to help employers make informed decisions across self-funded health plans, not to treat one disclosure rule as a cure-all. In a self-funded vs fully insured evaluation, employers should consider their data access, plan control, risk tolerance, and stop loss insurance alongside pharmacy contract terms.
Benefits do not have to be confusing. We partner with employers and their brokers: the broker advises on strategy, and Quilt runs the plan. Competitive national provider network access is part of the foundation; data-driven management is what helps employers put more control behind the plan. For companies seeking health insurance for small business or a stronger benefits package for employees, a better view of costs can support more affordable employee benefits while protecting the value employees rely on.
Looking further ahead, the Consolidated Appropriations Act, 2026, requires 100% pass-through of rebates, fees, alternative discounts, and other remuneration for plan years beginning on or after August 3, 2028. Two caveats matter: the Department of Labor has indicated that spread compensation may fall outside that pass-through, and the law also lets certain fully insured plans opt in rather than excluding them outright. So 2028 is not simply “everything flows through.” The 2027 disclosure rule is the nearer milestone, and the opportunity to build a stronger review process now.
Curious what your plan could save?
Pharmacy cost visibility is one part of the picture. Explore how your plan data and cost-management opportunities could support a more confident benefits strategy.
Explore the Quilt Benefits Employee Benefits Guide & Calculator to generate a custom savings report for your organization.
